(-0.88%) 4 967.23 points
(0.56%) 37 986 points
(-2.05%) 15 282 points
(0.62%) $83.24
(0.17%) $1.760
(0.36%) $2 406.70
(1.29%) $28.75
(-1.17%) $943.30
(-0.14%) $0.938
(-0.28%) $11.01
(0.55%) $0.808
(-0.96%) $93.00
Live Chart Being Loaded With Signals
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke...
Stats | |
---|---|
Today's Volume | 21 009.00 |
Average Volume | 40 976.00 |
Market Cap | 90.72M |
EPS | $0 ( 2024-03-26 ) |
Next earnings date | ( $-0.160 ) 2024-05-20 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.98 |
ATR14 | $0.0170 (0.71%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-22 | Lorianne Masuoka K. | Buy | 285 000 | Stock option (right to buy) |
2024-01-22 | Lorianne Masuoka K. | Buy | 0 | |
2024-01-02 | Semba Charles Pauling | Buy | 9 375 | Voting Common Shares, no par value per share |
2024-01-02 | Kuntz Richard | Buy | 14 285 | Voting Common Shares, no par value per share |
2024-01-02 | Pilnik Richard D. | Buy | 30 357 | Voting Common Shares, no par value per share |
INSIDER POWER |
---|
52.85 |
Last 91 transactions |
Buy: 8 059 792 | Sell: 2 870 847 |
Volume Correlation
DiaMedica Therapeutics Correlation
10 Most Positive Correlations | |
---|---|
GSIT | 0.944 |
APYX | 0.943 |
EXAS | 0.942 |
SPSC | 0.94 |
MDB | 0.939 |
PCYG | 0.937 |
BSY | 0.933 |
IESC | 0.933 |
EWZS | 0.931 |
SGH | 0.929 |
10 Most Negative Correlations | |
---|---|
PAIC | -0.931 |
ONEM | -0.93 |
BLTE | -0.925 |
SVOK | -0.922 |
SOPA | -0.919 |
ONCR | -0.903 |
SVAC | -0.899 |
JRJC | -0.898 |
CIIG | -0.895 |
SBNYP | -0.888 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
DiaMedica Therapeutics Correlation - Currency/Commodity
DiaMedica Therapeutics Financials
Annual | 2023 |
Revenue: | $0 |
Gross Profit: | $-30 000.00 (0.00 %) |
EPS: | $-0.600 |
Q4 | 2023 |
Revenue: | $0 |
Gross Profit: | $-8 000.00 (0.00 %) |
EPS: | $-0.140 |
Q3 | 2023 |
Revenue: | $0 |
Gross Profit: | $-5.16M (0.00 %) |
EPS: | $-0.120 |
Q2 | 2023 |
Revenue: | $0 |
Gross Profit: | $-4.74M (0.00 %) |
EPS: | $-0.160 |
Financial Reports:
No articles found.
DiaMedica Therapeutics
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators